期刊
JOURNAL OF NANOBIOTECHNOLOGY
卷 20, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12951-022-01244-9
关键词
Mitochondria-targeting; Hypoxia-activated prodrug; Phototherapy; Combination therapy; Drug delivery
资金
- National Natural Science Foundation of China [21807024]
- Youth Top-notch Talents Supporting Plan of Hebei Province [QNBJ19004]
- Hundred Persons Plan of Hebei Province [E2018050012]
- Natural Science Foundation of Hebei Province [H2020206059]
- Hebei Province High School Science and Technology Research Project [ZD2021072]
- Science Fund for Creative Research Groups of Natural Science Foundation of Hebei Province [H2020206474]
By combining photodynamic therapy, photothermal therapy, and hypoxia-activated chemotherapy, this study developed a mitochondrial targeted nanoplatform that can synergistically treat tumors and maximize the therapeutic window.
Despite considerable progress has been achieved in hypoxia-associated anti-tumor therapy, the efficacy of utilizing hypoxia-activated prodrugs alone is not satisfied owing to the inadequate hypoxia within the tumor regions. In this work, a mitochondrial targeted nanoplatform integrating photodynamic therapy, photothermal therapy and hypoxia-activated chemotherapy has been developed to synergistically treat cancer and maximize the therapeutic window. Polydopamine coated hollow copper sulfide nanoparticles were used as the photothermal nanoagents and thermosensitive drug carriers for loading the hypoxia-activated prodrug, TH302, in our study. Chlorin e6 (Ce6) and triphenyl phosphonium (TPP) were conjugated onto the surface of the nanoplatform. Under the action of TPP, the obtained nanoplatform preferentially accumulated in mitochondria to restore the drug activity and avoid drug resistance. Using 660 nm laser to excite Ce6 can generate ROS and simultaneously exacerbate the cellular hypoxia. While under the irradiation of 808 nm laser, the nanoplatform produced local heat which can increase the release of TH302 in tumor cells, ablate cancer cells as well as intensify the tumor hypoxia levels. The aggravated tumor hypoxia then significantly boosted the anti-tumor efficiency of TH302. Both in vitro and in vivo studies demonstrated the greatly improved anti-cancer activity compared to conventional hypoxia-associated chemotherapy. This work highlights the potential of using a combination of hypoxia-activated prodrugs plus phototherapy for synergistic cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据